Chimeric single-chain variable fragment-human immunoglobulin G crystallizable fragment antibody against GD2 for neuroblastoma targeted immunotherapy.
Witida LaopajonNuchjira TakheawKamonporn KotemulSupansa PataSuradej HongengWatchara KasinrerkPublished in: Exploration of targeted anti-tumor therapy (2023)
The results indicate that chimeric scFv-hIgG Fc antibody, lacking heavy chain CH1 domain, could mediate antibody induced anti-tumor activities. The small size of this type of chimeric antibody may be employed as anti-GD2 antibody for NB therapy.